ISATUXIMAB-BASED THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
- 1Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
- 2Universidade de Caxias do Sul, Porto Alegre, RS, Brazil
- 3Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
Abstract
Background: Isatuximab, an anti-CD38 monoclonal antibody, has demonstrated promising efficacy in newly diagnosed multiple myeloma. However, evidence regarding its effects on treatment response, progression-free survival, stem-cell mobilization, and safety remains limited. This systematic review and meta-analysis evaluated the efficacy and safety of isatuximab-based therapy in patients with newly diagnosed multiple myeloma. Methods: A PRISMA-compliant systematic review and meta-analysis was conducted. PubMed/MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library were systematically searched from inception. Seven studies involving 2,626 patients with newly diagnosed multiple myeloma were included. Random-effects meta-analyses were performed to estimate pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) for efficacy and safety outcomes. Results: Isatuximab-based therapy demonstrated consistent efficacy across multiple clinically meaningful outcomes in patients with newly diagnosed multiple myeloma. Compared with standard treatment, the addition of isatuximab significantly increased the likelihood of achieving MRD negativity following induction and consolidation (OR 1.99, 95% CI 1.52–2.60), indicating deeper treatment responses. Evidence from individual comparative studies further suggested improved rates of deeper MRD assessment at a sensitivity threshold of 10⁻⁶. These improvements in disease response translated into superior clinical outcomes, with a significant prolongation of progression-free survival (HR 0.70, 95% CI 0.52–0.95). Importantly, treatment intensification with isatuximab did not compromise stem-cell mobilization, as no significant difference was observed in stem-cell collection failure between treatment groups (OR 1.04, 95% CI 0.15–7.32). However, patients receiving isatuximab required plerixafor more frequently during mobilization (OR 1.70, 95% CI 1.08–2.67), suggesting that successful stem-cell collection was maintained with additional mobilization support when necessary. Regarding safety, isatuximab-based regimens were associated with a significantly higher incidence of grade ≥3 infections (OR 1.49, 95% CI 1.12–1.99). Grade ≥3 neutropenia was also more frequent in the comparative study reporting this outcome (OR 2.34, 95% CI 1.37–4.00). In contrast, no statistically significant differences were observed between treatment groups for grade ≥3 anemia (OR 1.34, 95% CI 0.30–6.10), thrombocytopenia (OR 0.82, 95% CI 0.34–1.96), serious adverse events (OR 1.12, 95% CI 0.65–1.95), or treatment discontinuation due to adverse events (OR 1.22, 95% CI 0.51–2.91). Sensitivity analyses demonstrated that the increased risk of grade ≥3 infections remained stable after sequential exclusion of individual studies, supporting the robustness of the pooled estimate. Overall, these findings indicate that the addition of isatuximab improves the depth of response and disease control while maintaining the feasibility of autologous stem-cell transplantation, with a manageable safety profile. Conclusion: Isatuximab-based therapy improves the depth of response and prolongs progression-free survival in patients with newly diagnosed multiple myeloma while preserving successful stem-cell mobilization. Although associated with a higher incidence of grade ≥3 infections and neutropenia, the overall safety profile remains manageable, supporting isatuximab-based regimens as an effective frontline treatment option.
Related
- EFFICACY AND SAFETY OF DARATUMUMAB IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
- ISATUXIMAB PLUS POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY PRIOR ANTI-CD38 EXPOSURE FROM THE PHASE 3 IRAKLIA TRIAL
- Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
- UPDATED RESULTS FROM THE PHASE 2 IZALCO STUDY: EFFICACY AND SAFETY OF ISATUXIMAB SUBCUTANEOUS PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
- The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma.
BibTeX
@article{almeida2026isatuximabbased,
title = {{ISATUXIMAB-BASED THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS}},
author = {Isadora Medeiros ALMEIDA and Maria Fernanda Gonçalves Meirelles FERNANDES and Carolina Marsiglia LUCINI and Lucas Mariano PINHEIRO and Flávia Penso BERGAMASCHI and Marina Fração PEREIRA and Júlia Muraro MARCHETTI and Guilherme Dalla CHIESA and Luís Fernando Franzen VINADE NETO and Jalise Wolski Oliveira ROMANOV},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2026},
month = oct,
doi = {10.1016/j.htct.2026.107883},
url = {https://doi.org/10.1016/j.htct.2026.107883},
note = {CC BY},
}
RIS
TY - JOUR
TI - ISATUXIMAB-BASED THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
AU - Isadora Medeiros ALMEIDA
AU - Maria Fernanda Gonçalves Meirelles FERNANDES
AU - Carolina Marsiglia LUCINI
AU - Lucas Mariano PINHEIRO
AU - Flávia Penso BERGAMASCHI
AU - Marina Fração PEREIRA
AU - Júlia Muraro MARCHETTI
AU - Guilherme Dalla CHIESA
AU - Luís Fernando Franzen VINADE NETO
AU - Jalise Wolski Oliveira ROMANOV
PY - 2026
DA - 2026/10/23
JO - Hematology, Transfusion and Cell Therapy
DO - 10.1016/j.htct.2026.107883
UR - https://doi.org/10.1016/j.htct.2026.107883
AB - Background: Isatuximab, an anti-CD38 monoclonal antibody, has demonstrated promising efficacy in newly diagnosed multiple myeloma. However, evidence regarding its effects on treatment response, progression-free survival, stem-cell mobilization, and safety remains limited. This systematic review and meta-analysis evaluated the efficacy and safety of isatuximab-based therapy in patients with newly diagnosed multiple myeloma. Methods: A PRISMA-compliant systematic review and meta-analysis was conducted. PubMed/MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library were systematically searched from inception. Seven studies involving 2,626 patients with newly diagnosed multiple myeloma were included. Random-effects meta-analyses were performed to estimate pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) for efficacy and safety outcomes. Results: Isatuximab-based therapy demonstrated consistent efficacy across multiple clinically meaningful outcomes in patients with newly diagnosed multiple myeloma. Compared with standard treatment, the addition of isatuximab significantly increased the likelihood of achieving MRD negativity following induction and consolidation (OR 1.99, 95% CI 1.52–2.60), indicating deeper treatment responses. Evidence from individual comparative studies further suggested improved rates of deeper MRD assessment at a sensitivity threshold of 10⁻⁶. These improvements in disease response translated into superior clinical outcomes, with a significant prolongation of progression-free survival (HR 0.70, 95% CI 0.52–0.95). Importantly, treatment intensification with isatuximab did not compromise stem-cell mobilization, as no significant difference was observed in stem-cell collection failure between treatment groups (OR 1.04, 95% CI 0.15–7.32). However, patients receiving isatuximab required plerixafor more frequently during mobilization (OR 1.70, 95% CI 1.08–2.67), suggesting that successful stem-cell collection was maintained with additional mobilization support when necessary. Regarding safety, isatuximab-based regimens were associated with a significantly higher incidence of grade ≥3 infections (OR 1.49, 95% CI 1.12–1.99). Grade ≥3 neutropenia was also more frequent in the comparative study reporting this outcome (OR 2.34, 95% CI 1.37–4.00). In contrast, no statistically significant differences were observed between treatment groups for grade ≥3 anemia (OR 1.34, 95% CI 0.30–6.10), thrombocytopenia (OR 0.82, 95% CI 0.34–1.96), serious adverse events (OR 1.12, 95% CI 0.65–1.95), or treatment discontinuation due to adverse events (OR 1.22, 95% CI 0.51–2.91). Sensitivity analyses demonstrated that the increased risk of grade ≥3 infections remained stable after sequential exclusion of individual studies, supporting the robustness of the pooled estimate. Overall, these findings indicate that the addition of isatuximab improves the depth of response and disease control while maintaining the feasibility of autologous stem-cell transplantation, with a manageable safety profile. Conclusion: Isatuximab-based therapy improves the depth of response and prolongs progression-free survival in patients with newly diagnosed multiple myeloma while preserving successful stem-cell mobilization. Although associated with a higher incidence of grade ≥3 infections and neutropenia, the overall safety profile remains manageable, supporting isatuximab-based regimens as an effective frontline treatment option.
SN - 2531-1379
SN - 2531-1387
ER -